The Pharma Navigator back issues.
Issue 9
Google Releases AlphaFold 3, Biopharma Continues to Fuel CDMO Growth
If you're tired of hearing about the latest advances in AI and how they are poised to revolutionize science, we are too. But just last week, some exciting updates emerged from the most successful scientific AI tool yet…
Issue 8
Growth forecasts for orphan drugs slow and AZ’s CEO calls out Europe
A report recently published by Evaluate titled “Are Orphan Drugs Losing Their Sparkle” might sound apprehensive, but it highlights why pharma companies can still expect plenty of promise and activity within the orphan drug sector…
Issue 7
Will biosimilars threaten Big Pharma dominance? Why is generic uptake so low?
As the industry looks to find more effective ways to manage the rising burden of genetic, autoimmune, rare diseases, and cancers, the next 10 years could be significant for companies with an interest in biologics drug products…
Issue 6
What's next for mRNA after COVID-19, and will there be any CDMOs left?
The COVID-19 pandemic brought its fair share of disruption and uncertainty; propelling biopharma-related topics into the public consciousness. The development of mRNA vaccines took centre stage. Investigated as potential treatments since the 1990s, companies like Moderna gave them top billing…
Issue 5
Will 2024 see more money for Biotech? What Medicare will mean for drug pricing, and on drugs losing exclusivity
Are we on the brink of a biotech renaissance? After a period of recalibration, the industry is showing signs of revival…
Issue 4
Is Changing Cannabis Legislation a Promising Sign for Pharmaceutical Cannabinoids?
Legalisation of cannabis has been a hot topic for many years already, and it doesn’t look like that is set to change…
Issue 3
ADC funding for cancer, investment for AI discovery platform & Super Bowl commercials you might have missed
Opioids have long been used for the treatment of pain management, yet their overuse and abuse causes real issues across global societies…
Issue 2
They say ‘you can’t outrun a bad diet,’ and you’ll be hard-pushed to stay ahead of news about weight-loss drugs too
You are probably well aware of the enthusiasm around weight-loss drugs; Wegovy, Ozempic and Zepbound to name a few. Their performance has raised interest in those who are considering using them for their same effects as lifestyle drugs…
Issue 21
What Threats Does Hurricane Season Bring to Pharma Supply Chains?
Hurricane Helene was the second major hurricane of the 2024 Atlantic hurricane season as it hit the southeastern United States just two weeks ago. Sadly, over 200 people have already lost their lives, and initial estimates suggest it to be the eighth costliest U.S. hurricane on record…
Issue 20
The Pharma Navigator CPHI Milan Edition – A Special Preview Edition for CPHI Milan
As 3,000 companies and 60,000 attendees finalize plans before heading to Milan for the 35th anniversary of CPHI, you might have started thinking about what’s on offer and who you are going to catch up with next week…
Issue 19
Here’s What to Expect from CPHI Milan
Celebrating its 35th year, CPHI Milan is expected to attract more than 62,000 biopharma professionals from all over the world, offering unmatched opportunities to connect with global innovators and leaders across the industry…
Issue 18
The Enduring Attraction of Oral Solid Dose
The first pills date back to roughly 1,500 BC, and whilst the pharmaceutical landscape continues to evolve, drug delivery via oral solid dosage (OSD) remains a dominant form due to the ease with which tablets are administered, patients’ familiarity with the dose form, and efficient manufacturing techniques…
Issue 17
CDMO Market Set for Unprecedented Growth Across Pharmaceuticals, Antibodies & Recombinant Proteins
Recently published reports (from The Brainy Insights & InsightAce Analytic Pvt. Ltd) suggest the CDMO industry is poised for significant growth that will continue into the next decade…
Issue 16
Identifying Trends Behind the Top Selling Pharma Drugs
Whilst we’re just past the halfway mark of 2024, mid-year analysis of the top selling drugs for the top 10 pharma companies provides some interesting insights into the demands of the market so far this year. Analysis from PharmaVoice shows that the leading drugs have generated over $55bn in revenue so far…
Issue 15
Are GLP-1 Drugs Becoming a Burden on National Healthcare?
It’s almost impossible for us to compile an edition of The Pharma Navigator without a major update surrounding GLP-1 drugs. Although it is no secret that drugs are generating significant revenue for Big Pharma, is it doing so at the expense of our national healthcare systems?…
Issue 14
Significant Growth Predicted for CDMO Market
A recently published report from Future Market Insights highlights significant potential for global CMO/CDMO market growth; with projections suggesting a significant increase in value from $22.5 bn in 2023 to $39.4 bn by 2033…
Issue 1
In our inaugural issue, we cover just some of the news stories that appeared in time for CPHI in Barcelona
Did we see ripples of cautious optimism from the JP Morgan conference? The industry is certainly ready for the small uplift in last year’s FDA approvals, and for biotech dealmaking to continue.
Why not sign up for our future email newsletters? Sign up here.
Issue 13
Injectable CDMO Market to Triple in the Next Decade
It wasn’t so very long ago that progress in delivering systemic treatments, via new oral technologies, inhalables, and via a plethora of alternative routes of delivery suggested that the days were numbered for invasive injections…
Issue 12
What’s Next in Biopharma After BIO 2024?
Did we see you at BIO 2024?
If you can’t recall more than a couple of weeks ago, or you were unfortunate to miss out this time around, we’re back with a one-off recap with some of the top stories we’ve come across since San Diego…
Issue 11
U.S. Drug Shortages Revealed & Can Bioprocessing Services Keep Up With Demand?
Ask any executive why they think there are drug shortages, and they will no doubt blame some combination of the long-lasting impact of the global pandemic, inflation, energy costs and global conflicts…
Issue 10
A BIO Preview Edition of The Pharma Navigator
In this newsletter special, we focus on the latest news from the last fortnight, and look forward to the BIO International Conference, happening in San Diego, on June 3 - 6; will we see you there? The BIO 2024 agenda is full of informative events and receptions - take advantage by looking at the schedule at a glance here…